DNA icon

Spastic Paraplegia 73 via the CPT1C Gene

Summary and Pricing

Test Method

Exome Sequencing with CNV Detection
Test Code Test Copy GenesTest CPT Code Gene CPT Codes Copy CPT Codes Base Price
CPT1C 81479 81479,81479 $990
Test Code Test Copy Genes Test CPT Code Gene CPT Codes Copy CPT Code Base Price
13321CPT1C81479 81479,81479 $990 Order Options and Pricing

An additional 25% charge will be applied to STAT orders. STAT orders are prioritized throughout the testing process.

Click here for costs to reflex to whole PGxome (if original test is on PGxome Sequencing platform).

Click here for costs to reflex to whole PGnome (if original test is on PGnome Sequencing platform).

Turnaround Time

3 weeks on average for standard orders or 2 weeks on average for STAT orders.

Please note: Once the testing process begins, an Estimated Report Date (ERD) range will be displayed in the portal. This is the most accurate prediction of when your report will be complete and may differ from the average TAT published on our website. About 85% of our tests will be reported within or before the ERD range. We will notify you of significant delays or holds which will impact the ERD. Learn more about turnaround times here.

Targeted Testing

For ordering sequencing of targeted known variants, go to our Targeted Variants page.


Genetic Counselors


  • Greg Fischer, PhD

Clinical Features and Genetics

Clinical Features

Hereditary spastic paraplegia (HSP) is a group of clinically and genetically diverse diseases, characterized by bilateral lower extremity spasticity (rigid muscles) and weakness (Fink et al. 2014. PubMed ID: 25192507; Hensiek et al. 2015. PubMed ID: 25480570; Hedera. 2018. PubMed ID: 20301682). HSP is classified as “pure” or “uncomplicated” when symptoms are confined to lower extremity spasticity and weakness and hypertonic urinary bladder. In contrast, HSP is classified as “complex” or “complicated” if the impairments in the lower limbs are also accompanied by other systemic or neurologic abnormalities such as seizures, ataxia, intellectual disability, dementia, peripheral neuropathy, and vision and hearing impairment (Fink. 2014. PubMed ID: 25192507; Hedera. 2018. PubMed ID: 20301682). The incidence of all forms of HSP is estimated to be less than one in 10,000 individuals or 0.01% (Hensiek et al. 2015. PubMed ID: 25480570).

Symptoms of the disease may begin at any age, with early onset HSP starting in early childhood and often resembling spastic diplegic cerebral palsy and late onset HSP beginning later in childhood or early adulthood (Fink. 2014. PubMed ID: 25192507; Hedera. 2018. PubMed ID: 20301682). In addition to variation in the age of onset, the severity and rate of progression are highly variable among different subtypes of complex HSPs, and even within a specific subtype (Tesson et al. 2015. PubMed ID: 25758904).

Spastic paraplegia 73 (SPG73) is characterized by adult-onset spasticity and weakness of the lower limbs resulting in walking abnormalities, hyperreflexia with extensor plantar responses, and decreased vibratory sensation. Additional features may include muscle atrophy, urinary dysfunction, foot deformities, and motor delay (Rinaldi et al. 2015. PubMed ID: 25751282; D'Amore et al. 2018. PubMed ID: 30564185; Hong et al. 2019. PubMed ID: 30911584). SPG73 has been reported in a small number of patients. In addition to the adult-onset form of HSP, a congenital-onset form of HSP has been reported recently in a SPG73 family (Hong et al. 2019. PubMed ID: 30911584). Variable expressivity is documented even among family members who carry the same variant (Hong et al. 2019. PubMed ID: 30911584).

Advantages of genetic testing for HSP include confirmation of diagnosis, identification of other health risks associated with complicated HSP, targeted testing of other family members, and assistance with reproductive planning (Hedera. 2018. PubMed ID: 20301682).


To date, more than 90 genetic loci and over 70 genes have been shown to be involved in HSP (Tesson et al. 2015. PubMed ID: 25758904; de Souza et al. 2017. PubMed ID: 27271711). HSP may be inherited in an autosomal dominant (AD) (75% to 80% of cases), autosomal recessive (AR) manner (25% to 30%); or X-linked (XL) (1% to 2%) manner (Hensiek et al. 2015. PubMed ID: 25480570; Hedera et al. 2018. PubMed ID: 20301682). The genotype-phenotype correlation is poor, and some genes are associated with both complex and pure HSP (Fink. 2013. PubMed ID: 23897027).

SPG73 is inherited in an AD manner and is caused by pathogenic variants at the 19q13.33 locus in the CPT1C (carnitine palmitoyltransferase 1C) gene. To date, four variants (2 missense, 1 nonsense, and 1 splicing) in CPT1C have been reported in patients with SPG73 (Rinaldi et al. 2015. PubMed ID: 25751282; D'Amore et al. 2018. PubMed ID: 30564185; Hong et al. 2019. PubMed ID: 30911584). The exact mechanism of disease remains to be elucidated, although loss-of-function and dominant negative mechanisms have been proposed (Rinaldi et al. 2015. PubMed ID: 25751282; Hong et al. 2019. PubMed ID: 30911584). No definitive instances of de novo pathogenic variants have been reported.

An Italian study which conducted molecular screenings on 239 consecutive HSP index cases identified two patients with missense variants in CPT1C (D'Amore et al. 2018. PubMed ID: 30564185). Both missense variants were reported in few individuals in control population databases, which may be explained by the adult-onset conditions in SPG73 or incomplete penetrance.

The CPT1C gene encodes a carnitine palmitoyltransferase, which is localized to the endoplasmic reticulum. It was reported that CPT1C regulates late endosome/lysosome anterograde transport and axon growth in neurons (Palomo-Guerrero et al. 2019. PubMed ID: 31868590). CPT1C has been cited as a nonessential gene for growth of human tissue culture cells (Online Gene Essentiality, ogee.medgenius.info). Studies in homozygous knockout mice showed muscle weakness, ataxia, dyscoordination, spatial learning deficits, and impaired body energy homeostasis (Carrasco et al. 2012. PubMed ID: 22539351; Carrasco et al. 2013. PubMed ID: 23973755; Rodríguez-Rodríguez et al. 2019. PubMed ID: 30448371). Heterozygous knockout mice have not been characterized in the literature.

Clinical Sensitivity - Sequencing with CNV PGxome

Pathogenic variants in CPT1C appear to be a rare cause of spastic paraplegia. Approximately 40% of AD HSPs are caused by pathogenic variants in SPAST (Shribman et al. 2019. PubMed ID: 31377012), while variants in ATL1, KIF5A, and REEP1 make up another 20% of HSPs (Schlipf et al. 2010. PubMed ID: 20461110). It is expected that clinical sensitivity for SPG73 will be low.

Analytical sensitivity should be high as all reported pathogenic variants are detectable by sequencing.

Testing Strategy

This test is performed using Next-Generation sequencing with additional Sanger sequencing as necessary.

This test provides full coverage of all coding exons of the CPT1C gene plus 10 bases of flanking noncoding DNA in all available transcripts along with other non-coding regions in which pathogenic variants have been identified at PreventionGenetics or reported elsewhere. We define full coverage as >20X NGS reads or Sanger sequencing. PGnome panels typically provide slightly increased coverage over the PGxome equivalent. PGnome sequencing panels have the added benefit of additional analysis and reporting of deep intronic regions (where applicable).

Dependent on the sequencing backbone selected for this testing, discounted reflex testing to any other similar backbone-based test is available (i.e., PGxome panel to whole PGxome; PGnome panel to whole PGnome).

Indications for Test

Candidates for this test are patients manifesting features of AD spastic paraplegia. Targeted testing is indicated for family members of patients who have a known pathogenic variant in CPT1C.


Official Gene Symbol OMIM ID
CPT1C 608846
Inheritance Abbreviation
Autosomal Dominant AD
Autosomal Recessive AR
X-Linked XL
Mitochondrial MT


Name Inheritance OMIM ID
Spastic Paraplegia 73 AD 616282


  • Carrasco et al. 2012. PubMed ID: 22539351
  • Carrasco et al. 2013. PubMed ID: 23973755
  • D'Amore et al. 2018. PubMed ID: 30564185
  • de Souza et al. 2016. PubMed ID: 27271711
  • Fink. 2013. PubMed ID: 23897027
  • Fink. 2014. PubMed ID: 25192507
  • Hedera. 2018. PubMed ID: 20301682
  • Hensiek et al. 2015. PubMed ID: 25480570
  • Hong et al. 2019. PubMed ID: 30911584
  • Online Gene Essentiality (OGEE).
  • Palomo-Guerrero et al. 2019. PubMed ID: 31868590
  • Rinaldi et al. 2015. PubMed ID: 25751282
  • Rodríguez-Rodríguez et al. 2019. PubMed ID: 30448371
  • Schlipf et al. 2010. PubMed ID: 20461110
  • Shribman et al. 2019. PubMed ID: 31377012
  • Tesson et al. 2015. PubMed ID: 25758904


Ordering Options

We offer several options when ordering sequencing tests. For more information on these options, see our Ordering Instructions page. To view available options, click on the Order Options button within the test description.

myPrevent - Online Ordering

  • The test can be added to your online orders in the Summary and Pricing section.
  • Once the test has been added log in to myPrevent to fill out an online requisition form.
  • PGnome sequencing panels can be ordered via the myPrevent portal only at this time.

Requisition Form

  • A completed requisition form must accompany all specimens.
  • Billing information along with specimen and shipping instructions are within the requisition form.
  • All testing must be ordered by a qualified healthcare provider.

For Requisition Forms, visit our Forms page

If ordering a Duo or Trio test, the proband and all comparator samples are required to initiate testing. If we do not receive all required samples for the test ordered within 21 days, we will convert the order to the most effective testing strategy with the samples available. Prior authorization and/or billing in place may be impacted by a change in test code.

Specimen Types

Specimen Requirements and Shipping Details

PGxome (Exome) Sequencing Panel

PGnome (Genome) Sequencing Panel

loading Loading... ×


An error has occurred while calculating the price. Please try again or contact us for assistance.

View Ordering Instructions

1) Select Test Method (Platform)

1) Select Test Type

2) Select Additional Test Options

No Additional Test Options are available for this test.

Note: acceptable specimen types are whole blood and DNA from whole blood only.
Total Price: loading
Patient Prompt Pay Price: loading
A patient prompt pay discount is available if payment is made by the patient and received prior to the time of reporting.
Show Patient Prompt Pay Price
Copy Text to Clipboard